% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • bionesteggs bionesteggs Aug 8, 2013 7:25 AM Flag

    No later than August 13, 2013

    On July 30, 2013, the Company entered into an Agreement and Plan of Merger, or Merger Agreement, with Cubist Pharmaceuticals, Inc., a Delaware corporation, or Cubist, and BRGO Corporation, a Delaware corporation and a wholly owned subsidiary of Cubist, or Purchaser, pursuant to which, and on the terms and subject to the conditions thereof, among other things, Purchaser will commence a tender offer, or Offer, no later than August 13, 2013 to acquire all of the outstanding shares of common stock of the Company at a purchase price of (a) $13.50 per share in cash, or Closing Amount, without interest, plus (b) one non-transferrable contingent value right for each share of the Company’s common stock, each a CVR, which represents the contractual right to receive up to $2.00 per share upon the achievement of certain milestones, such amount together with the Closing Amount is referred to as the Offer Price, subject to any required withholding of taxes. Following the completion of the Offer and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, including, if required, receipt of approval by the stockholders of the Company, Purchaser will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Cubist, or the Merger.

    Sentiment: Strong Buy